1445879-21-9
1445879-21-9 structure
- Name: GSK 2837808A
- Chemical Name: GSK2837808A
- CAS Number: 1445879-21-9
- Molecular Formula: C31H25F2N5O7S
- Molecular Weight: 649.621
- Catalog: Signaling Pathways Metabolic Enzyme/Protease Lactate Dehydrogenase
- Create Date: 2018-04-01 02:10:02
- Modify Date: 2024-01-07 15:55:11
-
GSK2837808A is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50s of 1.9 and 14 nM for LDHA and LDHB, respectively.
| Name | GSK2837808A |
|---|---|
| Synonyms |
3-{[3-(Cyclopropylsulfamoyl)-7-(2,4-dimethoxy-5-pyrimidinyl)-4-quinolinyl]amino}-5-(3,5-difluorophenoxy)benzoic acid
Benzoic acid, 3-[[3-[(cyclopropylamino)sulfonyl]-7-(2,4-dimethoxy-5-pyrimidinyl)-4-quinolinyl]amino]-5-(3,5-difluorophenoxy)- |
| Description | GSK2837808A is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50s of 1.9 and 14 nM for LDHA and LDHB, respectively. |
|---|---|
| Related Catalog | |
| Target |
IC50: 1.9 nM (LDHA), 1.9 nM (LDHB)[1] |
| In Vitro | GSK2837808A rapidly and profoundly inhibits lactate production rates in multiple cancer cell lines including hepatocellular and breast carcinomas. The potency of GSK2837808A across 30 cancer cell lines with different LDHA and LDHB expression levels ranges from 400 nM to no effect (EC50 reported as 30 μM). GSK2837808A potency does not correlate with LDHA, LDHB, or the total LDH expression levels. GSK2837808A inhibits lactate production in hypoxia but at higher concentrations than in normoxia (EC50=10 μM). It also reduces ECAR with EC50=10 μM. LDH inhibition by GSK2837808A alters multiple metabolic pathways in Snu398 cells[1]. |
| In Vivo | Clearance following IV infusion of GSK2837808A at 0.25 mg/kg is shown to be 69 mL/minute/kg in rats, which exceeds the animal liver blood flow. Oral dosing of GSK2837808A at 50 mg/kg in rats or 100 mg/kg in mice results in blood compound levels at or below the detection limit of 2.5 ng/mL[1]. |
| Cell Assay | Sixty thousand Snu398 cells per well are plated in 6-well tissue culture plates in RPMI-1640 medium supplemented with 2.5% charcoal-stripped FBS. Cells are allowed to attach overnight and then DMSO control or the indicated doses of LDHA inhibitor dissolved in DMSO are added directly to the wells. After 4 to 8 days of incubation in the indicated oxygen conditions, adherent cells are trypsinized, counted, and had their viability assessed by the trypan-blue exclusion method using the Vi-Cell XR Cell Viability Analyzer[1]. |
| Animal Admin | Mice: GSK2837808A is administered to male CD mice or male Sprague-Dawley rats orally or by intravenous (IV) infusion over 120 minutes into a femoral vein. Arterial blood samples are collected over time and GSK2837808A concentration is determined by liquid chromatography (LC)/MS/MS analysis[1]. |
| References |
| Density | 1.6±0.1 g/cm3 |
|---|---|
| Boiling Point | 783.5±70.0 °C at 760 mmHg |
| Molecular Formula | C31H25F2N5O7S |
| Molecular Weight | 649.621 |
| Flash Point | 427.6±35.7 °C |
| Exact Mass | 649.144287 |
| LogP | 7.60 |
| Vapour Pressure | 0.0±2.9 mmHg at 25°C |
| Index of Refraction | 1.710 |
| Storage condition | 2-8℃ |